Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR12000 Compound Tablets in Moderate to Severe Essential Hypertension
NCT07700875Phase 2Completed
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Countries
- 1
01
Overview
A Phase 2 trial of QR12000 in essential hypertension, sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Dec 2022; status: completed.
02
Drugs
QR12000
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07700875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700875.